Study | Finding | Sample size | EDRN stage | Grade of evidence |
---|---|---|---|---|
Weston et al 2001359 | Kaplan–Meier curves differed significantly between p53-positive and -negative patients for outcome defined as progression of LGD | Progressors n=5, non-progressors n=43 | Prospective phase 4 | IIa |
Murray et al 2006196 | OAC/HGD end point: OR 8.42 (95% CI 2.37 to 30.0) | Progressors n=35, controls n=175 | Phase 3: retrospective | IIa |
SIkkema et al 2009198 | HR 6.5 (95% CI 2.5 to 17.1) Remained a risk factor on multivariable analysis | Progressors n=27, non-progressors n=27 | Prospective phase 4 | IIa |
Younes et al 1997370 | Progression from LGD to HGD/OAC, p=0.0108. p53 accumulation has a sensitivity of 100%, specificity of 93%, and a predictive value of a positive test of 0.56 | Progressors n=5, non-progressors n=25 | Phase 3: retrospective | IIa |
Skacel et al 2002130 | Progression from LGD to HGD/OAC. A correlation with clinical progression was seen, p=0.017 (88% sensitivity and 75% specificity for progression) | Progressors n=8, non-progressors n=8 | Phase 3: retrospective | IIa |
Bani-Hani 2000197 | OR=2.99 (95% CI=0.57 to 15.76; p=0.197). | Nested case–control (unmatched), n=12 cases | Phase 3: retrospective | IIa |
Kastelein 2012131 | RR=6.2 (95% CI=3.6 to 10.9) | Progressors n=49, non-progressors n=586 | Phase 3: retrospective | IIa |
HGD, high-grade dysplasia; HR, hazard ratio; LGD, low-grade dysplasia; OAC, oesophageal adenocarcinoma; OR, odds ratio.